undamentalytics Newsletter
Sign in

Kiniksa Pharmaceuticals International, plc income statement

In fiscal 2025, Kiniksa Pharmaceuticals International, plc reported revenue of $678m, up 60.1% on the year before, operating income of $77.2m (a 11.4% margin) and net income of $59.0m, or $0.75 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue39220270423678946
Cost of revenue92333617893
Gross profit29197237362600853
Research and development99657611297136
Selling, general and administrative8698129168196247
Operating income−15710−25−4677130
Income before tax−15711−17−3689146
Income tax1−172−3173037
Net income−15818314−4359110
Diluted EPS−$2.30$2.60$0.20−$0.60$0.75$1.32
Diluted shares (average)69m70m72m71m79m83m
EBITDA−15412−23−4479132

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BBIO vs KNSABCRX vs KNSAIONS vs KNSAKNSA vs LEGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Kiniksa Pharmaceuticals International, plc's SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Kiniksa Pharmaceuticals International, plc.